Portal de Periódicos da CAPES

Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies

2006; Springer Science+Business Media; Linguagem: Inglês

10.1007/978-1-60761-058-8_6

1940-6029

Derry C. Roopenian, Gregory J. Christianson, Thomas J. Sproule,

Glycosylation and Glycoproteins Research

Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies.